Hohenberger P, Rathmann N, Busing K, Menge F, Jakob J, Pink D
Br J Cancer. 2025; .
PMID: 40044980
DOI: 10.1038/s41416-025-02952-3.
Wu X, Yamashita K, Matsumoto C, Zhang W, Ding M, Harada K
J Gastroenterol. 2024; 60(3):275-284.
PMID: 39557657
DOI: 10.1007/s00535-024-02180-1.
De Biase D, De Leo M, Piegari G, dAquino I, Di Napoli E, Mercogliano C
Vet Sci. 2024; 11(10).
PMID: 39453084
PMC: 11512316.
DOI: 10.3390/vetsci11100492.
Boichuk S, Dunaev P, Galembikova A, Valeeva E
Cancers (Basel). 2024; 16(17).
PMID: 39272961
PMC: 11394061.
DOI: 10.3390/cancers16173103.
Heinrich M, Jones R, George S, Gelderblom H, Schoffski P, von Mehren M
Nat Med. 2024; 30(2):498-506.
PMID: 38182785
PMC: 10878977.
DOI: 10.1038/s41591-023-02734-5.
FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1.
Wu X, Iwatsuki M, Takaki M, Saito T, Hayashi T, Kondo M
Gastric Cancer. 2023; 27(2):235-247.
PMID: 38142463
DOI: 10.1007/s10120-023-01454-6.
Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary Mutations.
Boichuk S, Dunaev P, Skripova V, Galembikova A, Bikinieva F, Shagimardanova E
Cancers (Basel). 2023; 15(22).
PMID: 38001614
PMC: 10670741.
DOI: 10.3390/cancers15225354.
Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review.
Zhang Y, Huang Z
Front Pharmacol. 2023; 14:1122885.
PMID: 37288114
PMC: 10242384.
DOI: 10.3389/fphar.2023.1122885.
LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib.
Ruiz-Demoulin S, Trenquier E, Dekkar S, Deshayes S, Boisguerin P, Serrano C
Int J Mol Sci. 2023; 24(8).
PMID: 37108337
PMC: 10138740.
DOI: 10.3390/ijms24087138.
Liver transplantation for metastatic non-resectable gastrointestinal stromal tumor after molecular targeted therapies: A case report.
Li H, Meng X, Zhang K, Tang H
Int J Surg Case Rep. 2022; 95:107185.
PMID: 35576749
PMC: 9112116.
DOI: 10.1016/j.ijscr.2022.107185.
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous Mutations in the Phase III INVICTUS Study.
Bauer S, Heinrich M, George S, Zalcberg J, Serrano C, Gelderblom H
Clin Cancer Res. 2021; 27(23):6333-6342.
PMID: 34503977
PMC: 9401492.
DOI: 10.1158/1078-0432.CCR-21-1864.
KIT Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor.
Banerjee S, Yoon H, Ting S, Tang C, Yebra M, Wenzel A
Mol Cancer Ther. 2021; 20(10):2035-2048.
PMID: 34376580
PMC: 8492542.
DOI: 10.1158/1535-7163.MCT-20-0973.
Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors.
Gupta A, Ma S, Che K, Pobbati A, Rubin B
PLoS One. 2021; 16(7):e0252689.
PMID: 34324512
PMC: 8320897.
DOI: 10.1371/journal.pone.0252689.
Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.
Bauer S, George S, von Mehren M, Heinrich M
Front Oncol. 2021; 11:672500.
PMID: 34322383
PMC: 8313277.
DOI: 10.3389/fonc.2021.672500.
GMP-compliant production of [Ga]Ga-NeoB for positron emission tomography imaging of patients with gastrointestinal stromal tumor.
Pretze M, Reffert L, Diehl S, Schonberg S, Wangler C, Hohenberger P
EJNMMI Radiopharm Chem. 2021; 6(1):22.
PMID: 34228236
PMC: 8260665.
DOI: 10.1186/s41181-021-00137-w.
Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors.
Qian X, Yan Y, Gao B, Wang W
World J Gastroenterol. 2020; 26(40):6195-6206.
PMID: 33177793
PMC: 7596635.
DOI: 10.3748/wjg.v26.i40.6195.
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours.
Saito Y, Takahashi T, Obata Y, Nishida T, Ohkubo S, Nakagawa F
Br J Cancer. 2019; 122(5):658-667.
PMID: 31857719
PMC: 7054534.
DOI: 10.1038/s41416-019-0688-y.
Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
Liu W, Zeng X, Yin Y, Li C, Yang W, Wan W
Gastric Cancer. 2019; 23(1):39-51.
PMID: 31197522
DOI: 10.1007/s10120-019-00977-1.
Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib: A systematic review.
Xie F, Xiao W, Jiang Y, Xia X, Wang Y
Medicine (Baltimore). 2019; 98(19):e15478.
PMID: 31083182
PMC: 6531104.
DOI: 10.1097/MD.0000000000015478.
Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer.
Kaserer T, Blagg J
Cell Chem Biol. 2018; 25(11):1359-1371.e2.
PMID: 30146241
PMC: 6242700.
DOI: 10.1016/j.chembiol.2018.07.013.
